You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com
and Hepatitis.com Coverage of the
50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010)
End-of-Treatment Response to Interferon-based Therapy Reduces Liver Failure and Death in HIV/HCV Coinfected Patients
Juan Berenguer and fellow investigators with the GESIDA 3603 Cohort Study Group looked at the impact of end-of-treatment response (ETR), or undetectable HCV viral load at the completion of therapy, on liver-related outcomes among study participants who did not go on to achieve sustained virological response (SVR), or continued undetectable HCV RNA at 24 weeks after the end of treatment (considered a cure).
Previous research has shown that sustained response to pegylated interferon plus ribavirin reduces liver-related complications such as decompensation (liver failure) and liver-related death among coinfected patients, the researchers noted as background, but the effects of end-of-treatment response without SVR are not well known.
The present analysis looked at 1428 HIV/HCV coinfected participants in the GESIDA 3603 Cohort who were treated with pegylated interferon/ribavirin at 9 centers in Spain. Observation started at the conclusion of treatment and continued until death or the last follow-up visit. The median follow-up period was about 4 years.
Based on these findings, the investigators concluded, the best outcomes were achieved among patients who achieved SVR, but ETR was associated with less liver-related mortality and decompensation than non-response.
Hosp Gregorio Maranon, Madrid, Spain; Hosp La Paz, Madrid, Spain; Hosp Vall d'Hebron, Barcelona, Spain; Hosp Clínico de San Carlos, Madrid, Spain; Hosp. Univ. Rio de Guadalajara, Guadalajara, Spain; Hosp Severo Ochoa, Madrid, Spain; Hosp. de Getafe, Getafe, Spain; Fundación SEIMC GESIDA, Madrid, Spain.